



Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review

Judith R. Harrison^{a,*}, Sanchita Bhatia^b, Zhao Xuan Tan^b, Anastasia Mirza-Davies^b,
Hannah Benkert^b, Chantal M.W. Tax^a, Derek K. Jones^{a,c}

^a Cardiff University Brain Research Imaging Centre (CUBRIC), Maindy Road, Cardiff CF24 4HQ, UK

^b Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK

^c Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia

ARTICLE INFO

Keywords:

Alzheimer's Disease
Magnetic Resonance Imaging
Diffusion Tensor Imaging
Apolipoproteins E
Presenilin-1
Presenilin-2
Multifactorial Inheritance

ABSTRACT

Diffusion magnetic resonance imaging (dMRI) is an imaging technique which probes the random motion of water molecules in tissues and has been widely applied to investigate changes in white matter microstructure in Alzheimer's Disease. This paper aims to systematically review studies that examined the effect of Alzheimer's risk genes on white matter microstructure. We assimilated findings from 37 studies and reviewed their diffusion pre-processing and analysis methods. Most studies estimate the diffusion tensor (DT) and compare derived quantitative measures such as fractional anisotropy and mean diffusivity between groups. Those with increased AD genetic risk are associated with reduced anisotropy and increased diffusivity across the brain, most notably the temporal and frontal lobes, cingulum and corpus callosum. Structural abnormalities are most evident amongst those with established Alzheimer's Disease. Recent studies employ signal representations and analysis frameworks beyond DT MRI but show that dMRI overall lacks specificity to disease pathology. However, as the field advances, these techniques may prove useful in pre-symptomatic diagnosis or staging of Alzheimer's disease.

1. Introduction

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder affecting older adults. It is characterised by amyloid plaques, hyperphosphorylated tau and atrophy (Braak and Braak, 1995). Histopathological studies have also identified AD pathology in white matter (Englund, Brun and Alling, 1988). In recent years, diffusion Magnetic Resonance Imaging (dMRI) has been used to examine white matter microstructure in AD and to study the effect of AD genetic risk on white matter microstructure.

1.1. Alzheimer's disease genetic risk

Sporadic AD, often called late-onset AD, is the most common form of dementia, affecting 1 in ten people over the age of 65 (Alzheimer's Association, 2019). The heritability of sporadic AD is estimated to be between 58 and 79% (Gatz et al., 2006). The largest genome-wide association study (GWAS) of clinically confirmed AD has identified 25 loci that are associated with increased risk for sporadic AD (Kunkle et al., 2019). These are common genetic variants, known as single nucleotide polymorphisms (SNPs). The largest of these genetic risks are

SNPs in the Apolipoprotein E (APOE) region. Carriers of two copies of the APOE Epsilon 4 (APOE E4) allele have an eight-fold increase in risk compared to non-carriers (Corder et al., 1993). In comparison to APOE, other common risk loci have only a modest effect on disease risk. However, their combined effect can be studied using polygenic risk scores. These are calculated from the weighted sum of weighted allelic dosages across the genome, and have proven particularly effective in predicting AD (Escott-Price et al., 2015). In addition to common genetic risk captured by GWAS, advances in sequencing techniques have assessed entire exomes and genomes, identifying rare mutations with moderate-to-strong effects. For example, TREM2 is a variant that encodes the trigger receptor expressed on myeloid cells 2 (Guerreiro et al., 2013). Other novel variants are involved in immune response and transcriptional regulation (Bis et al., 2018).

Whilst sporadic AD occasionally occurs in people under the age of 65, autosomal-dominant AD is characterised by an early clinical onset. In contrast to sporadic AD, autosomal-dominant AD is rare (Alzheimer's Association, 2019). It is caused by mutations either in the amyloid precursor protein (APP) gene, or in presenilin 1 and 2 (PS1 and PS2) that are involved in cleaving amyloid β and APP. The disease onset is often predictable, depending on the specific mutation (Tanzi, 2012).

* Corresponding author.

E-mail address: harrisonjr1@cardiff.ac.uk (J.R. Harrison).

<https://doi.org/10.1016/j.nicl.2020.102359>

Received 23 December 2019; Received in revised form 20 June 2020; Accepted 20 July 2020

Available online 22 July 2020

2213-1582/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1.2. Diffusion MRI

dMRI is a non-invasive imaging method that probes the movement of water molecules to assess the microstructural configuration of white matter tracts (Jones, 2011; Winston, 2012). dMRI measures indicate how readily water molecules can diffuse in and around structures such as white matter fibres or cell bodies (Stejskal and Tanner, 1965; Bihan, 1995; Strijkers, Drost and Nicolay, 2011; Johansen-Berg and Behrens, 2013). In white matter, the rate of diffusion is modulated by multiple microstructural features including axon diameter, axon density and myelination (Jones, 2011). In highly ordered white matter, the rate of diffusion is anisotropic, i.e., it is strongly dependent on the direction in which it is measured. The commonly index of anisotropy is the fractional anisotropy (FA) introduced by Basser and Pierpaoli (Basser and Pierpaoli, 1996). An FA of 0 indicates that the rate of diffusion is the same in all directions (isotropic diffusion), and 1 represents the extreme case where diffusion can only occur along one axis (anisotropic diffusion) (Beaulieu and Allen, 1994; Pierpaoli and Basser, 1996; Beaulieu, 2009; Winston, 2012). Clinical studies often employ this as a measure of tissue integrity (Thomason and Thompson, 2011), although at best this interpretation is an oversimplification (Jones, Knösche and Turner, 2013). Another widely used metric is mean diffusivity (MD), which represents the orientationally-averaged rate of diffusion. Additional commonly used metrics from DTI are the 'longitudinal diffusivity' (LD) and 'radial diffusivity' (RD), which in turn represent the highest and lowest rates of diffusion. In the case of perfectly aligned axonal bundles, these would represent diffusivity parallel and perpendicular to the main axis of the bundle, respectively. However, given the ubiquity of multiple fibre populations within an image voxel, this interpretation carries some risk (see: Wheeler-Kingshott and Cercignani, 2009) but also see (Wheeler-Kingshott et al., 2012). Collectively, FA, MD, LD and RD can help to characterise changes in diffusion resulting from differences in white matter microstructure.

1.3. Structural changes observed in Alzheimer's disease

Conventional MRI measures of atrophy, such as Voxel-Based Morphometry (VBM), are established markers for AD diagnosis and measurement of progression (Frisoni et al., 2010). More recently, dMRI has allowed the exploration of AD white matter microstructure, finding widespread changes. A meta-analysis of 41 studies found reduced FA and increased MD in AD brains compared to controls. Differences were marked in frontal and temporal lobes, and the posterior cingulum, corpus callosum, superior longitudinal fasciculi and uncinate fasciculi (Sexton et al., 2011). Late-myelinating tracts may be affected primarily by AD neurodegeneration (Benitez et al., 2014). Longitudinal studies suggest that the pattern of decreased FA and increased MD becomes more distinct as the disease progresses (Mayo et al., 2017). Changes in the parahippocampal cingulum have been shown to discriminate between AD and healthy controls (Mayo et al., 2017). Diffusion measurements in the fornix are another possible biomarker (Ringman et al., 2007). Perea and colleagues found that AD preferentially degraded the crus and body of the fornix. The diffusion differences remained after controlling for fornix volume (Perea et al., 2018).

Mild Cognitive Impairment (MCI) describes a degree of cognitive problems that do not affect day-to-day living, and are considered to be an AD prodrome (Petersen and Morris, 2005). A meta-analysis of 41 studies found that compared to healthy controls, patients with MCI had lower FA in all white matter areas except parietal and occipital regions, and higher MD except in occipital and frontal regions (Sexton et al., 2011). More recently, whole brain white matter histogram analysis found that RD, LD and MD were able to discriminate between AD and controls and between MCI and controls in the ADNI cohort. LD appeared to be the most sensitive marker (Giulietti et al., 2018).

dMRI metrics in the fornix are markers of cognitive problems, and can distinguish MCI from AD (Egli et al., 2015; Tang et al., 2017). The

volume of the body of the fornix and LD in the fornix are correlated with decline from normal cognition (Fletcher et al., 2013). Reduced FA in the fornix can predict conversion both from healthy cognition to MCI and from MCI to AD with high specificity and > 90% accuracy (Mielke et al., 2012; Oishi et al., 2012). Reduced FA and increased MD in the fornix might even precede hippocampal atrophy (Zhuang et al., 2012).

1.4. Current review

This systematic review aimed to collate studies applying diffusion MRI techniques to investigate genetic risk for AD. In our narrative synthesis, our goal is to assess the evidence for manifestations of Alzheimer's genetic risk in white matter microstructure. We also aim to review the studies in terms of their study design and diffusion methodology, including pre-processing and analysis.

2. Methods

We conducted this systematic review in accordance with PRISMA guidelines (Moher et al., 2009).

2.1. Study selection

Initially, we defined our search terms (listed in Table 1, Supplementary Materials). We searched the literature using MEDLINE, PSYCHINFO and EMBASE from January 2000-July 2019. We hand-searched the reference lists of related articles.

Inclusion criteria:

- Case-control, cross-sectional or longitudinal studies
- Genotyped participants
- Imaged with dMRI sequences
- Associations reported between AD risk genes/SNPs and measures derived from dMRI

Exclusion criteria:

- Publications in non-English language journals
- Conference proceedings
- Studies of non-Alzheimer's dementia or unspecified dementia
- Studies using family history and genotype as a composite variable
- Studies using MRI but not including dMRI
- Studies investigating genes/SNPs that are not associated with AD risk
- Studies that co-vary for AD genes (e.g. APOE) but that do not report associations with AD risk genes/SNPs

2.2. Article selection

The articles included in this review are all English language original research papers. Study designs included case-control, cross-sectional and longitudinal studies. The primary search was conducted by SB. Five reviewers (SB, HB, AMD, ZXT, JH) all independently selected studies based on the eligibility criteria. Disagreements were resolved by consensus.

2.3. Data extraction

Reviewers (SB, HB, AMD, ZXT, JH) extracted information from papers independently. Data were extracted from each study in duplicate to ensure consistency. Key data included: study design and number of participants the AD genetic risk measured; MRI acquisition parameters; dMRI pre-processing; dMRI analysis techniques; reported findings. A complete list of the data extracted can be found in Supplementary Materials Table 2.




Fig. 1. PRISMA flow chart.

2.4. Quality assessment

The quality of each included study was assessed independently by two reviewers using the appropriate version of the Newcastle-Ottawa Scale (NOS) (Stang, 2010) for the study design (case/control, cross-sectional or cohort study). The NOS assesses the quality of non-randomized studies in three main areas: the selection of study groups; the comparability of the groups; and the ascertainment of the exposure or outcome of interest. This tool was chosen because of the type of studies included. A consensus meeting between all reviewers established a manual to ensure this was applied consistently. The assessment tool was adapted to fit the included studies, where the exposure was defined as genetic risk, and important covariates were age, sex and APOE e4 status. A point was awarded in each category.

3. Results

3.1. Search results

We identified 2931 articles in our initial search (see PRISMA flow diagram in Fig. 1). We excluded duplicates, non-English language, non-human studies and conference proceedings. 2514 articles were screened based on their titles and abstracts and a further 2394 were excluded. The reviewers (SB, HB, AMD, ZXT, JH) reviewed the full text of 120 articles and applied the inclusion criteria. 32 studies met the criteria for inclusion. A further 4 studies were identified through hand-searches of reference lists.

3.2. Study characteristics: Study design, sample, Alzheimer's genetic risks

The majority of the studies were case/control design, although some were cross-sectional (Foley et al., 2016) and some longitudinal cohort studies (Lyll et al., 2014). Some studies were conducted using the same cohorts: three used data from the Beijing Aging Brain Rejuvenation Initiative (BABRI); two used the Wisconsin Registry for Alzheimer's Prevention (WRAP); two used the European Diffusion Tensor Imaging Study on Dementia (EDSA) and the DZNE database, Rostock, Germany. Only one article reported data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Most studies included participants who were pre-symptomatic. Only ten included those with established AD or MCI.

3.3. Genotypes

Two approaches were used to assess genetic risk for AD. Most studies tested participants for specific mutations (APP, PS1/2 mutations or APOE alleles). One study used an array to genotype participants and calculate polygenic risk scores based on sporadic AD GWAS (Foley et al., 2016).

3.4. dMRI pre-processing and analysis methods

Prior to modelling or statistical analysis, it is essential to pre-process the dMRI data, correcting for artefacts, motion and eddy-current induced distortions (Jones, Knösche and Turner, 2013). Once pre-processed, different approaches can be applied to represent the dMRI signal. Beyond the diffusion tensor framework, two common ways to represent the orientation dependence of the signal in dMRI are the

diffusion orientation density function (dODF) (Wedeen et al., 2005) and the fibre orientation density function (fODF) (Dell'Acqua et al., 2019). The diffusion ODF is a spherical function which characterises the probability of diffusion along a unit direction. On the other hand, the fODF is a function that characterises the probability of finding a fibre oriented along a particular axis (Jones et al., 2013).

An additional method, known as neurite orientation dispersion and density imaging (NODDI), aims to provide more specific microstructural information (Zhang et al., 2012). NODDI assumes there are three biophysical compartments in white matter, intra-cellular, extra-cellular and cerebrospinal fluid, in a single voxel. By imposing constraints on some of the parameters that describe these compartments, NODDI aims to estimate proxies of intracellular volume fraction (IVF), neurite density index (NDI), orientational dispersion index (NDI) and increased free isotropic water fraction (FISO) (Zhang et al., 2012).

Quantitative dMRI measures, such as FA, MD, RD and LD (all derived from the diffusion tensor), can be analysed using tractography or whole-brain voxel-wise analysis. Tractography involves reconstructing the trajectory of fibres and connection patterns, using either the principal eigenvector of the diffusion tensor, or peaks in the dODF or fODF, within successive adjacent voxels (Tournier, Mori and Leemans, 2011; Jones, Knösche and Turner, 2013). These local orientations are used to infer total fibre trajectories (Jeurissen et al., 2019). Commonly used methods include deterministic and probabilistic tractography. In deterministic tracking, a path is propagated along local maxima of the ODF (or, in the case of diffusion tensor imaging, along the principal eigenvector). However, imaging noise and artifacts can make estimates of local maxima imprecise and adds some local orientational uncertainty. Probabilistic tractography techniques illustrate these uncertainties by assigning an uncertainty, or conversely, a probability to the orientational estimates. As such, each local maximum in an ODF can generate a collection of possible trajectories (Jeurissen et al., 2019).

A tractography-based region-of-interest (ROI) approach allows the researcher to define 'seeds' to begin fibre tracking, or to define 'way-points' that prescribe regions through which a reconstructed tract must pass in order to be retained for analysis (Conturo et al., 1999). These can be drawn manually or automatically. Alternatively, whole-brain tractography places seeds throughout the whole brain (Soares et al., 2013), again using 'way-point' ROIs to filter out target pathways. In tractography, each tract is segmented in the native of the individual (rather than requiring that the individual's data are co-registered to some standardised template space, providing a representation of tract anatomy for each individual (Bastin et al., 2013)). It is important to recognise that the reconstructed tracts do not represent nerve fibres or fibre bundles directly. Rather, they represent pathways or trajectories through the signal, and we infer that the nerve fibres run approximately in parallel. These pathways can be translated into qualitative information, e.g., on the tract shape, and into quantitative information, as measures averaged along the tract (Jones and Pierpaoli, 2005) or in assessing the extent of connections between brain regions (Kaden, Knösche and Anwender, 2007).

Whole brain voxel-based techniques, such as Tract Based Spatial Statistics (TBSS) (Smith et al., 2006, 2007) or Voxel-Based Analysis (VBA) (Büchel et al., 2004; Van Hecke et al., 2009), are an alternative approach to tractography. They typically involve the nonlinear registration of quantitative diffusion tensor imaging maps, (e.g. FA), from each individual to a standard template space. The aligned FA images are then averaged, and a skeletonised mean FA structure is created. Thresholds are applied to suppress areas of low mean FA or high inter-subject variation. Each subject's FA image is then projected onto the skeleton, and voxel-wise statistics can be carried out across subjects. For comprehensive descriptions of these different dMRI methods and possible pitfalls, please see (Smith et al., 2006; Jones, Knösche and Turner, 2013; Soares et al., 2013).

Inter-regional connectivity can be assessed by constructing networks of the human brain using diffusion signals and tractography (Yeh

et al., 2020). The resultant networks can be characterised using graph theoretical approaches. Graph theory is a mathematical framework for representing complex networks. The brain can be illustrated using nodes, representing regions or voxels, and edges, representing connections between nodes (Bullmore and Sporns, 2009). A number of network metrics can be produced such as small-world and network efficiency. Please see (Boccaletti et al., 2006) for a detailed summary of graph theory.

The studies that met our inclusion criteria used a range of dMRI analysis methods. 15 used TBSS, seven used a tractography-based ROI approach, eight used VBA, three combined TBSS and VBA, one combined TBSS and ROI, and three calculated structural connectivity matrices.

3.5. Studies of white matter structure and APOE status

The majority of the papers which met our inclusion criteria explored the effects of APOE (27 articles). Most used a case-control design, although some were longitudinal studies. There was a wide range of sample sizes (N range = 14–885). The literature predominantly examined samples of cognitively healthy older adults (age > 60). Five studies included participants with diagnoses of AD or MCI (Bagepally et al., 2012a,b; Kljajevic et al., 2014; Wai et al., 2014; Ma et al., 2017; Slattery et al., 2017). Studies of younger age groups included adolescents (Dell'Acqua et al., 2015), adults in their 20's (Heise et al., 2011; O'Dwyer et al., 2012; Dowell et al., 2013), 40's and 50's (Westlye et al., 2012; Operto et al., 2018). Some studies were able to compare groups with different combinations of APOE alleles (Lyall et al., 2014), although most simply compared APOE E4 carriers (homozygotes and heterozygotes) to those without an E4 allele. Diffusion methodology included: TBSS (12 studies); tractography-based ROI (6 studies); VBA (4 studies); TBSS and VBA (3 studies); TBSS and ROI (1 study); structural connectivity (3 studies). Table 1 provides a summary of studies exploring white matter metrics and APOE genotype.

Five studies reported no significant differences in white matter microstructure between carriers and non-carriers (Honea et al., 2009; Bendlin et al., 2012; Nyberg and Salami, 2014; Dell'Acqua et al., 2015; Wang et al., 2015). All other studies reported some significant changes in diffusion metrics associated with APOE4. The pattern of alteration in affected tracts or regions was similar to studies of autosomal-dominant AD genes: reduced FA was commonly reported, often in tandem with increased MD, RD or LD. Reduced neurite density index (NDI) and increased free isotropic water fraction (FISO) are also reported. The white matter regions found to be associated with APOE status included: the genu (Newlander et al., 2014; Zhang et al., 2015; Cai et al., 2017; Cavedo et al., 2017), body (Persson et al., 2006; Zhang et al., 2015) and splenium (Ryan et al., 2011; Slattery et al., 2017) of the corpus callosum and the corpus callosum overall (Heise et al., 2011; Westlye et al., 2012; Cavedo et al., 2017); the parahippocampal cingulum (Nierenberg et al., 2005; Bagepally et al., 2012a,b; Kljajevic et al., 2014; Zhang et al., 2015) and the cingulum overall (Adluru et al., 2014; Lyall et al., 2014; Cavedo et al., 2017); the intracalacrine sulcus (Bagepally et al., 2012a,b; Westlye et al., 2012); the brain stem (Westlye et al., 2012; Newlander et al., 2014); the corona radiata (Heise et al., 2011; Smith et al., 2016; Cai et al., 2017; Cavedo et al., 2017; Slattery et al., 2017; Operto et al., 2018); the external capsule (Heise et al., 2011; Cavedo et al., 2017) and internal capsule (Heise et al., 2011; Westlye et al., 2012; Smith et al., 2016; Cavedo et al., 2017); the superior longitudinal fasciculus (Adluru et al., 2014; Lyall et al., 2014; Cavedo et al., 2017; Operto et al., 2018) and inferior longitudinal fasciculus (Dowell et al., 2013; Cavedo et al., 2017); the fronto-occipital fasciculus (Cavedo et al., 2017; Operto et al., 2018); the fornix (Zhang et al., 2015); the cerebral peduncles (Zhang et al., 2015); the corticospinal tract (Laukka et al., 2015); the uncinate fasciculus (Salminen et al., 2013); the forceps major (Laukka et al., 2015) and forceps minor (Operto et al., 2018).

Table 1
Summary of sample characteristics, methodology and main findings for studies of APOE.

| Study | N (E4 carriers; non-carriers) | Age (SD) | dMRI Method | Field Strength (T) | B value (s/mm ²) | Acquisition Voxel Size (mm) | N Directions | NEX | Regions of Interest | Results |
|------------------------|-------------------------------|---|-------------------------|--------------------|------------------------------|-----------------------------|------------------|-----|---|--|
| Aduru et al, 2014 | 343 (123; 220) | 61.03 (6.72) | ROI | 3 | 0, 1300 | 2.5 × 2.5 × 2.5 | 40 | 1 | Fornix, splenium & genu of corpus callosum, cingulum, uncinate, superior longitudinal fasciculus. | • Older (> 65) carriers vs. non-carriers: ↑ MD in SLF & cingulum bundle |
| Bagepally et al, 2012 | 32 (19; 13) | 69.3 (5.7) | TBSS | 3 | 0, 1000 | Not reported | 32 | 1 | Whole brain | • AD carriers vs. AD non-carriers: ↓ FA in left medial temporal areas, parahippocampal cingulum, bilateral intracalcarine sulcus, precuneus, lingual area • Healthy carriers vs. healthy non-carriers: ↓ FA bilateral medial temporal areas, scattered regions in frontal & parietal lobes & cerebellum |
| Bendlin et al, 2010 | 136 (56; 80) | 69.2 (10.2) | VBA | 3 | 0 | 2 × 2 × 3 | 12 | 1 | Whole brain | • Carriers vs. non-carriers: no significant differences |
| Brown et al, 2011 | 55 (25; 30) | 62.3 (9.0) | Structural connectivity | 3 | 800 or 1000 | 2.5 × 2.5 × 2.5 | 30 | 1 | Global & regional connectivity | • Carriers vs. non-carriers: age-related loss of mean local interconnectivity, & regional local interconnectivity decreases in the precuneus, medial orbitofrontal cortex, & lateral parietal cortex. |
| Cai et al, 2017 | 309 (116; 193) | 73.9 (4.6) | VBA | 3 | Not reported | 1.02 × 1.02 × 1.02 | Not reported | 1 | Superior corona radiata, genu of corpus callosum | • Carriers vs. non-carriers: ↑ MD in superior corona radiata, genu of corpus callosum. No significant associations with FA or RD |
| Cavedo et al, 2017 | 74 (31; 43) across 4 centres | 68.9 (6.9) | TBSS, VBA | 1.5 or 3 | 0, 1000 or 0, 800 | 2 × 2 × 2 or 1 × 1 × 2.4 | 12, 15, 20 or 60 | 1 | Whole brain | • Carriers vs. non-carriers: ↓ FA globally, and in genu, body & splenium of corpus callosum, internal capsule, external capsule, inferior fronto-occipital & inferior longitudinal fasciculi, cingulum (left & right). ↑ MD in right hemisphere, in genu of corpus callosum, right internal capsule, right corona radiata, right superior longitudinal fasciculus. ↑ RD globally, & bilaterally in genu & splenium of corpus callosum, internal capsule, inferior fronto-occipital & inferior longitudinal fasciculi, cingulum, external capsule |
| Chen et al, 2016 | 75 (35; 40) | 65.8 (7.5) | Structural connectivity | 3 | 0, 1000 | Not reported | 30 | 3 | Whole brain structural network | • Carriers vs. controls: lower global efficiency, no significant differences in local efficiency. Decreased nodal efficiency in left anterior cingulate, left paracingulate gyrus, right dorsolateral superior frontal gyrus, left inferior occipital gyrus |
| Dell'Acqua et al, 2015 | 575 (119; 374) | 14.4 (0.5) | TBSS | 3 | 0, 1300 | 2.4 × 2.4 × 2.4 | 60 | 1 | Whole brain | • Case/control prediction: ROC AUC for global efficiency 0.74; decreasing region 0.81 |
| Dowell et al, 2013 | 41 (20; 21) | 20.0 (2.0) | TBSS | 1.5 | 0, 1000 | 2.5 × 2.5 × 2.5 | 30 | 1 | Whole brain | • Carriers vs. non-carriers: no significant differences |
| Heise et al, 2010 | 71 (33; 38) | Young cohort 28.6 (4.2); Older cohort: 64.9 (7.2) | TBSS | | 1000 | 1.1 × 0.9 × 3 | | 1 | Whole brain | • Carriers vs. controls: ↑ RD in carriers, particularly in inferior longitudinal fasciculus. No significant differences in FA or MD. • Young carriers vs. non-carriers: ↓ FA in cingulum, corona radiata, corpus callosum, external capsule, internal capsule, superior longitudinal fasciculus • Older carriers vs. non-carriers: ↑ MD in |

(continued on next page)

Table 1 (continued)

| Study | N (E4 carriers; non-carriers) | Age (SD) | dMRI Method | Field Strength (T) | B value (s/mm ²) | Acquisition (mm) | Voxel Size (mm) | N Directions | NEX | Regions of Interest | Results |
|------------------------|-------------------------------|-------------|-------------------------|--------------------|------------------------------|-------------------------------------|-----------------|--------------|-----|--|---|
| Honea et al, 2009 | 53 (14; 39) | 73.4 (6.3) | TBSS | 3 | 0, 1000 | 1 × 1 × 1 | 1 × 1 × 1 | 12 | 1 | Whole brain | cingulum, corona radiata, corpus callosum, external capsule, internal capsule, superior longitudinal fasciculus • All carriers vs. non-carriers: ↓ FA in cingulum, corona radiata, corpus callosum, external capsule, internal capsule, superior longitudinal fasciculus • Carriers vs. non-carriers: no significant differences |
| Kljajevic et al, 2014 | 126 (63; 63) across 5 centres | 67.7 (5.9) | VBA | 1.5 + 3 | 0, 800 or 0, 1000 | 2 × 2 × 2, 2 × 2 × 2.5 or 2 × 2 × 3 | | 6 or 20 | 1 | Whole brain | • Healthy carriers vs. healthy non-carriers: ↑ MD in left lentiform nucleus • AD carriers & AD non-carriers: ↓ FA in middle frontal areas, insular white matter, superior temporal areas • Carriers vs. non-carriers: ↓ FA in forceps major, ↑ MD in corticospinal tract |
| Laukka et al, 2015 | 89 (23; 66) | 81.4 (3.0) | TBSS | 1.5 | 600 | 1 × 1 × 1 | 1 × 1 × 1 | 6 | 1 | Cingulate gyrus part of cingulum, parahippocampal cingulum, corticospinal tract, forceps major & minor, inferior fronto-occipital fasciculus, superior longitudinal fasciculus | |
| Lyall et al, 2014 | 645 (187; 423) | 72.7 (0.7) | ROI | 1.5 | 0, 1000 | 1.8 × 1.8 × 1.8 | | 64 | 1 | Genu & splenium of corpus callosum, bilateral anterior thalamic radiations, ventral & rostral cingulum bundles, & arcuate, uncinate, & inferior longitudinal fasciculi. | • Carriers vs. non-carriers: ↓ FA in right ventral cingulum & left inferior longitudinal fasciculus |
| Ma et al, 2017 | 885 (145; 729) | 65.3 (7.4) | Structural connectivity | 3 T | 1000 | Not reported | | 30 | 1 | Whole brain structural network | • Healthy carriers vs healthy non-carriers: ↑ clustering coefficient & local efficiency • MCI carriers vs. non-carriers: ↓ clustering coefficient & local efficiency • All carriers vs. non-carriers: ↓ nodal efficiency in: inferior frontal gyrus, orbital part; left superior frontal gyrus, orbital part; left middle occipital gyrus. ↑ nodal efficiency in: left cuneus; left inferior parietal but supramarginal and angular gyri • Carriers vs. non-carriers: ↓ FA in genu of corpus callosum & brain stem • Carriers vs. non-carriers: ↓ FA & ↑ RD in parahippocampal cingulum • Carriers vs. controls: no significant difference for whole brain metrics or specific subregion metrics in TBSS. ↓ FA in five anterior and posterior midline regions on VBA • Carrier vs. non-carrier: no significant differences in diffusion indices • Carrier/non-carrier prediction accuracy: sensitivity & specificity range 93–100% using a feature selection algorithm, support vector machines & FA data • Carriers vs. non-carriers: ↑ MD, RD & LD in corona radiata, superior longitudinal fasciculus, inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, corticospinal tract |
| Newlander et al, 2014 | 14 (7; 7) | 72.7 (6.1) | VBA | 1.5 | 0, 800 | 1 × 1 × 1 | 1 × 1 × 1 | 12 | 1 | Whole brain | |
| Nierenberg et al, 2005 | 29 (14; 15) | 67.1 (6.5) | ROI | 1.5 | 0, 1000 | Not reported | | 20 | 1 | Parahippocampal cingulum | |
| Nyberg et al, 2014 | 273 (69; 204) | 67.01 (8.0) | TBSS, VBA | 3 | 1000 | 0.98 × 0.98 × 2 | | 32 | 1 | Whole brain | |
| ODwyer et al, 2012 | 44 (22; 22) | 26.7 (4.0) | TBSS | 3 | 1000 | 2 × 2 × 2 | | 60 | 1 | Whole brain | |
| Operto et al, 2018 | 532 (275; 257) | 58.1 (7.5) | TBSS | 3 | 0, 1000 | 2 × 2 × 2 | | 64 | 1 | Whole brain | |
| | 60 (30; 30) | 66.3 (7.7) | ROI | | 1000 | Not reported | | 6 | 1 | | |

(continued on next page)

Table 1 (continued)

| Study | N (E4 carriers; non-carriers) | Age (SD) | dMRI Method | Field Strength (T) | B value (s/mm ²) | Acquisition (mm) | Voxel Size | N Directions | NEX | Regions of Interest | Results |
|----------------------|-------------------------------|-------------|-------------|--------------------|------------------------------|------------------|------------|--------------|-----|---|---|
| Persson et al, 2006 | | | | | | | | | | Whole brain analysis; genu, splenium, body of corpus callosum | • Carriers vs. non-carriers: ↓ FA in occipito-frontal fasciculus, body of corpus callosum |
| Ryan et al, 2011 | 126 (36; 88) | 69.2 (10.2) | ROI | 3 | 0, 1000 | 2.6 × 2.6 × 2.6 | 25 | 2 | | Frontal white matter, lateral parietal white matter, centrum semiovale, genu of the corpus callosum, splenium of the corpus callosum, temporal stem white matter. | • Carriers vs. non-carriers: no significant difference in LD, ↓ FA in frontal white matter & splenium |
| Salminen et al, 2013 | 64 (23; 41) | 61.75 (7.6) | ROI | 3 | 0, 996 | 2 × 2 × 2 | 31 | 1 | | Left uncinate fasciculus, right uncinate fasciculus, temporal lobe | • Carriers vs. controls: ↓ fibre bundle length in left uncinate fasciculus |
| Slattery et al, 2017 | 37 (22; 15) | 61.7 (5.0) | TBSS, ROI | 3 | 1000 | 2.5 × 2.5 × 2.5 | 64 | 1 | | Quadrants (anterior, posterior, left & right) | • AD carriers vs. AD non-carriers: ↓ FA in splenium of corpus callosum & anterior corona radiata. ↑ RD in white-matter projections from frontal lobes. More widespread ↓ NDI in parieto-occipital white-matter projections. ↑ FISO in corpus callosum |
| Smith et al, 2016 | 88 (34; 53) | 74.1 (4.5) | TBSS | 3 | 0, 1000 | 1 × 1 × 1 | 25 | 2 | | Longitudinal fasciculus, sagittal stratum, uncinate fasciculus, cingulate gyrus, parahippocampal cingulumformix, body, genu & splenium of corpus callosum, internal capsule, corona radiata | • Healthy carriers vs. non-carriers: no significant differences |
| Wai et al, 2014 | 120 (22; 98) | 68.9 (7.7) | TBSS | 3 | 1000 | 2 × 2 × 2 | 64 | 1 | | Whole brain | • Carriers vs. non-carriers: no significant effects on FA, LD or MD. ↑ RD in right anterior internal capsule, bilateral posterior corona radiata, left superior corona radiata. |
| Wang et al, 2015 | 241 (73; 126) | 72.0 (9.0) | TBSS | 1.5 | 0, 600 | 1 × 1 × 1 | 6 | 1 | | Whole brain | • Amnesic MCI carriers vs. controls: ↓ FA & ↑ MD |
| Westlye et al, 2012 | 203 (60; 143) | 47.6 (14.9) | TBSS | 1.5 | 1000 | 2 × 2 × 2 | 60 | 1 | | Whole brain | • Carriers vs. non-carriers: no significant differences |
| Zhang et al, 2015 | 75 (35; 40) | 65.9 (7.5) | TBSS, VBA | 3 | 0, 1000 | 2 × 2 × 2 | 30 | 1 | | Genu, body, splenium of corpus callosum, anterior & posterior corona radiate, fornix, cerebral peduncles, parahippocampal cingulum | • Carriers vs. non-carriers: increased RD brainstem, basal temporal lobe, internal capsule, anterior parts of the corpus callosum, forceps minor, superior longitudinal fasciculus, occipital & corticospinal pathways. |

Please note that we report findings from the most rigorous analyses conducted by studies, including models controlling for multiple comparisons. When not otherwise reported, NEX was assumed to be 1. Acronyms: dMRI = diffusion Magnetic Resonance Imaging; E4 = APOE Epsilon 4; TBSS = Tract-Based Spatial Statistics; VBA = Voxel-Based Analysis; ROI = Region of Interest; FA = Fractional Anisotropy; MD = Mean Diffusivity; RD = Radial Diffusivity; LD = Longitudinal Diffusivity; NDI = Neurite Dispersion Index; FISO = Free Isotropic Water Fraction; ROC = Receiver Operating Characteristic; AUC = Area Under Curve.

Three papers used measures of structural connectivity based on graph theory. Brown et al found that APOE E4 carriers had age-related loss of mean local interconnectivity and regional local interconnectivity in the precuneus, medial orbitofrontal cortex, and lateral parietal cortex (Brown et al., 2011). Ma et al studied participants with MCI and with normal cognition. They found that healthy APOE E4 carriers had increased clustering coefficient and local efficiency compared to healthy non-carriers. In those with MCI, carriers showed decreased clustering coefficient and local efficiency relative to MCI non-carriers. When all carriers were compared to all non-carriers, they showed decreased nodal efficiency in the inferior frontal gyrus, the left superior frontal gyrus, and the left middle occipital gyrus. Carriers also showed increased nodal efficiency in the left cuneus, the left inferior parietal, supramarginal and angular gyri (Ma et al., 2017). A further study reported that E4 carriers had lower global efficiency but no significant differences in local efficiency. Decreased nodal efficiency in left anterior cingulate, left paracingulate gyrus, right dorsolateral superior frontal gyrus, and left inferior occipital gyrus was reported in carriers relative to non-carriers. In addition, they used structural connectivity measures to predict AD with Receiver-Operator Curves (ROC). Using global efficiency, they produced an Area Under Curve (AUC) of 0.74. Using mean nodal efficiency of significant decreasing regions, this improved to 0.81 (Chen et al., 2015).

3.6. Studies of white matter and autosomal-dominant AD genes

Six studies explored white matter metrics in participants with autosomal-dominant AD genes: three studied PS1 carriers, two studied APP and PS1 carriers and one studied PS1, PS2 and APP carriers. All used a case/control design. They compared pre-symptomatic and symptomatic gene carriers to non-carriers. Sample sizes reflect the rarity of the genes (N range = 20–109, of which 10–64 were carriers). Three studies used VBA, three used TBSS.

Of the three studies of PS1 carriers, one study identified reduced MD and LD in the right cingulum among pre-symptomatic carriers (Ryan et al., 2013), and the other two studies reported no significant differences between pre-symptomatic PS1 and non-carriers (Parra et al., 2015; Sanchez-Valle et al., 2016). In symptomatic PS1 carriers, changes included: increased MD, RD and LD and reduced FA in all the fornix, cingulum and corpus callosum (Ryan et al., 2013); higher MD in the left inferolateral frontal white matter, right parahippocampal cingulum bundle, splenium left of the mid-line and genu symmetrically around the mid-line of the callosum (Parra et al., 2015); decreased FA in the genu and body of corpus callosum and corona radiata bilaterally and increased MD, LD, and RD in the splenium of corpus callosum relative to age (Sanchez-Valle et al., 2016).

Two studies with mixed cohorts of PS1 or APP carriers reported a number of changes in pre-symptomatic carriers: reduced FA in the fornix and frontal white matter (Ringman et al. 2007); increased MD in the left inferior longitudinal fasciculus, left forceps major, left cingulum and bilateral superior longitudinal fasciculus (Li et al., 2015). In the same PS1/APP studies, symptomatic carriers showed: decreased mean FA across the whole brain, especially in the left frontal white matter, and right and left perforant paths (Ringman et al. 2007); increased MD in the inferior longitudinal fasciculus, forceps major, cingulum and bilateral superior longitudinal fasciculus (Li et al., 2015). The effects seen in the symptomatic APP/PS1 carriers were greater and more widespread than in pre-symptomatic carriers (Ringman et al., 2007; Li et al., 2015). Caballero et al studied a large mixed cohort of PS1/2 and APP carriers. They found increased MD in the forceps minor, forceps major and long projecting fibres 5–10 years before the estimated onset of symptoms (Caballero et al., 2018). See Table 2 for a summary of these studies.

3.7. Studies of white matter and AD risk loci from GWAS

Three studies correlated white matter metrics with AD risk loci identified through GWAS. One was cross-sectional and two were case/control studies. They all included healthy participants (Mean age range 23.6–72.7; N range 197–645). Two studies used an ROI approach, one used VBA.

Braskie et al. imaged healthy young adults and found that each C allele copy of the *CLU* allele was associated with lower FA in the splenium of the corpus callosum, the fornix, cingulum, and superior and inferior longitudinal fasciculi bilaterally (Braskie et al., 2011). The Lothian Birth cohort study identified lower FA associated with different length genotypes of the poly-T repeat in TOMM40. Shorter genotypes were significantly associated with lower FA in the right rostral cingulum and left ventral cingulum. This effect was independent of *APOE* genotype (Lyall et al., 2014). Foley et al used an Alzheimer's polygenic score, the weighted sum of the risk loci from GWAS, as a continuous variable. They identified an association between increased AD polygenic score and decreased FA in the right cingulum in young adults (Foley et al., 2016).

Elliot et al undertook a GWAS of brain imaging phenotypes in the UK Biobank cohort (Elliott et al., 2018). They used imaging data from around 15,000 participants. All results are available on the Oxford Brain Imaging Genetics (BIG) web browser (<http://big.stats.ox.ac.uk/>). The BIG website can be browsed associations by phenotype, gene or SNP. We explored the associations between AD risk loci identified in the Kunkle et al GWAS (Kunkle et al., 2019) and FA/MD derived from TBSS in UK Biobank. A table summarising these results is provided in the Supplementary Materials. Broadly, the results corroborate the findings of other studies included in this review. APOE and CR1 showed particular evidence of association with reduced fractional anisotropy and increased mean diffusivity. However, these results are not corrected for multiple comparisons.

3.8. Study quality overview

Most studies scored highly on the NOS. Generally, the comparability of the groups was clearly explained. As the exposure was gene status, there was little possibility of ascertainment bias. Some studies had one point deducted for failing to describe the selection of study groups, particularly of control subjects. The outcomes of interest (white matter metrics) were defined, although the methodology employed to measure these was variable. It was often difficult to assess the quality of the diffusion methodology, as authors often did not provide sufficient information. Most studies gave some details of their pre-processing, although one acknowledged they had not corrected for Gibbs ringing, a common artefact (Gibbs, 1898). The papers generally did not give details of their model estimation technique (for example nonlinear least squares (NLLS), weighted linear least squares (WLLS) or ordinary least squares (OLS)), which can lead to different outcomes (Koay et al., 2006). The majority of studies, 27 of 37, used TBSS or VBA. Of those papers that used tractography, only some described or referenced the specific methods (such as deterministic or probabilistic).

4. Discussion




This review establishes that the literature reports AD genetic risk is related to altered white matter microstructure, as indexed by increased diffusivity and decreased anisotropy. By synthesising results across studies, this review demonstrates that AD risk genes were associated with widespread white matter changes, rather than discrete microstructural abnormalities in medial temporal structures such as the fornix. This review also found evidence of changes related to AD risk even in studies of young, healthy adults.

Table 2
Summary of sample characteristics, methodology and main findings for studies of FAD genes.

| Study | Gene | N (FAD carriers; non-carriers) | Mean Age (SD) | dMRI Method | Field Strength (T) | B value (s/mm ²) | Acquisition Voxel Size (mm) | N Directions | NEX | Region of Interest | Results |
|---------------------------|---------------|--------------------------------|---|-------------|--------------------|------------------------------|-----------------------------|--------------|-----|---|--|
| Caballero et al, 2018 | PS1, PS2, APP | 109 (64; 45) | Symptomatic & pre-symptomatic 38.8 (10.6); Non-carriers 38.0 (11.2) | TBSS | 3 | 0, 1000 | 0.9 × 0.9 × 5.0 | 64 | 1 | Whole brain | <ul style="list-style-type: none"> • Symptomatic & pre-symptomatic carriers: ↑ MD in posterior parietal & medial frontal regions |
| Li et al, 2015 | APP, PS1 | 30 (10; 20) | Symptomatic 46.5 (9.3); Pre-symptomatic 42.7 (8.4); Non-carriers 48.4 (15.1) | TBSS | 3 | 0, 1000 | 1 × 1 × 1 | 30 | 1 | Cingulum, superior longitudinal fasciculus, inferior longitudinal fasciculus | <ul style="list-style-type: none"> • Pre-symptomatic carriers vs controls: ↑ MD left inferior longitudinal fasciculus, left forceps major, right & left superior longitudinal fasciculus, left cingulum • Symptomatic & pre-symptomatic vs controls: pattern as above, differences ↑ |
| Parra et al, 2015. | PS1 | 58 (22; 14) | Symptomatic 47.5 (6.4); Pre-symptomatic 35.1 (5.5); Non-carriers 39.3 (8.3) | VBA | 1.5 | 0, 1000 | 1.72 × 1.72 × 3 | 12 | 1 | Parahippocampal cingulum, genu & splenium of corpus callosum, frontal white matter, parahippocampal cingulum, centrum semiovale | <ul style="list-style-type: none"> • Pre-symptomatic carriers vs controls: no significant differences • Symptomatic carriers vs controls: ↑ MD in parahippocampal cingulum, left splenium, genu bilaterally, left inferolateral frontal white matter |
| Ringman et al, 2007 | APP, PS1 | 20 (12; 8) | Symptomatic [age not reported]; Pre-symptomatic 32 (6.4); Non-carriers 36 (6.2) | VBA | 1.5 | 0, 1000 | 3 × 3 × 3 | 6 | 1 | Genu & splenium of corpus callosum, frontal white matter, fornix, cingulum, perforant path, corticospinal tract, whole brain | <ul style="list-style-type: none"> • Pre-symptomatic carriers vs controls: ↓ FA fornix & frontal white matter • Symptomatic & pre-symptomatic carriers vs controls: ↓ mean FA whole brain, ↓ FA left frontal white matter, right & left perforant path |
| Ryan et al, 2013 | PS1 | 40 (20; 20) | Symptomatic 49.0 (9.4); Presymptomatic 37.8 (4.7); Non-carriers 44.3 (12.7) | TBSS | 3 | 1000 | 1.1 × 1.1 × 1.1 | 64 | 1 | Fornix, cingulum, corpus callosum | <ul style="list-style-type: none"> • Pre-symptomatic carriers vs. controls: ↓ MD & RD in right cingulum • Symptomatic carriers vs controls: ↓ FA, ↑ MD & LD in all tracts |
| Sanchez-Valle et al, 2016 | PS1 | 36 (22; 14) | Symptomatic 46.63 (9.1); Pre-symptomatic 39.2 (10.4); Non-carriers 39.0 (9.5) | VBA | 3 | 0 | 2 × 2 × 2 | 30 | 1 | Whole brain | <ul style="list-style-type: none"> • Pre-symptomatic carriers vs controls: no significant differences • Symptomatic carriers vs controls: ↓ FA with ↑ relative age ratio in genu & body of corpus callosum & corona radiate; ↑ MD, LD, RD with ↑ relative age ratio in splenium |

Please note that we report findings from the most rigorous analyses conducted by studies, including models controlling for multiple comparisons. When not otherwise reported, NEX was assumed to be 1. Acronyms: dMRI = diffusion Magnetic Resonance Imaging; PS1 = Presenilin 1; APP = Amyloid Precursor Protein; TBSS = Tract-Based Spatial Statistics; VBA = Voxel-Based Analysis; ROI = Region of Interest; FA = Fractional Anisotropy; MD = Mean Diffusivity; RD = Radial Diffusivity; LD = Longitudinal Diffusivity.

Table 3
Summary of key findings for the most commonly implicated tracts by gene risk (APOE or FAD).

| Tract | Diagram | Summary of APOE Findings | Summary of FAD Findings |
|---|---|---|--|
| Corpus Callosum: Connects the left and right cerebral hemispheres |  | E4 carriers vs. non-carriers: ↓FA (Persson et al, 2006, Newlander et al, 2014, Heise et al, 2010, Cavedo et al, 2017, Zhang et al, 2015, Ryan et al, 2011, Slattery et al, 2017) ↑MD (Heise et al, 2010, Cavedo et al, 2017, Cai et al, 2017, Zhang et al, 2015) ↑RD (Cavedo et al, 2017, Westlye et al, 2012) | Pre-symptomatic carriers vs. controls: ↓FA (Sanchez-Valle et al, 2016) Symptomatic carriers vs. controls: ↑MD (Sanchez-Valle et al, 2016, Parra et al, 2015) ↑LD (Sanchez-Valle et al, 2016) ↑RD (Sanchez-Valle et al, 2016) |
| Cingulum: Connects the temporal and frontal lobes, cingulate and medial gyri of frontal, occipital, parietal and temporal lobes |  | E4 carriers vs. controls: ↓FA (Lyll et al, 2014, Bagepally et al, 2012, Heise et al, 2010, Cavedo et al, 2017, Nierenberg et al, 2005) ↑MD (Li et al, 2012, Zhang et al, 2015, Cavedo et al, 2017, Adluru et al, 2014) ↑RD (Cavedo et al, 2017, Nierenberg et al, 2005) | Pre-symptomatic carriers vs. controls: ↓MD (Ryan et al, 2013) ↑MD (Li et al, 2012) ↓LD (Ryan et al, 2013) Symptomatic carriers vs. controls: ↓FA (Ryan et al, 2013) ↑MD (Ryan et al, 2013, Parra et al, 2015, Li et al, 2012) ↑LD (Ryan et al, 2013) No significant findings |
| Inferior Occipito-Frontal Fascicle: Connects the medial temporal lobe and the inferior frontal lobe |  | E4 carriers vs. non-carriers: ↓FA (Persson et al, 2006, Cavedo et al, 2017) ↑MD (Operto et al, 2018) ↑LD (Operto et al, 2018) ↑RD (Cavedo et al, 2017, Westlye et al, 2012, Operto et al, 2018) | |
| Superior Longitudinal Fascicle: Connects the frontal, parietal, occipital and temporal lobes |  | E4 carriers vs. non-carriers: ↓FA (Heise et al, 2010) ↑MD (Adluru et al, 2014, Operto et al, 2018, Cavedo et al, 2017, Heise et al, 2010) ↑RD (Operto et al, 2018, Westlye et al, 2012) ↑LD (Operto et al, 2018) | Pre-symptomatic carriers vs. non-carriers: ↑MD (Li et al, 2012) Symptomatic carriers vs. non-carriers: ↑MD (Li et al, 2012) |
| Inferior Longitudinal Fascicle: Connects the occipital pole and temporal pole |  | E4 carriers vs. non-carriers: ↓FA (Lyll et al, 2014, Cavedo et al, 2017) ↑MD (Operto et al, 2018) ↑RD (Operto et al, 2018, Dowell et al, 2013, Cavedo et al, 2017) ↑LD (Operto et al, 2018) | Pre-symptomatic carriers vs. non-carriers: ↑MD (Parra et al, 2015, Li et al, 2012) Symptomatic carriers vs. non-carriers: ↑MD (Li et al, 2012) |

Acronyms: E4 = APOE Epsilon 4; FAD = Familial Alzheimer’s Disease; FA = Fractional Anisotropy; MD = Mean Diffusivity; RD = Radial Diffusivity; LD = Longitudinal Diffusivity. Tract images were generated using FiberNavigator (Chamberland et al., 2014) and TractSeg (Wasserthal et al., 2018).

4.1. White matter changes associated with AD risk genes

AD genetic risk is associated with reduced anisotropy and increased diffusivity across the brain, most notably in temporal and frontal lobes, cingulum and corpus callosum. Table 3 contains a summary of the five tracts that were implicated in the most studies (tract images were generated using FiberNavigator (Chamberland et al., 2014) and TractSeg (Wasserthal et al., 2018)). Although some studies reported no differences between pre-symptomatic gene carriers and non-carriers, many of these studies were limited by small sample sizes. Differences between symptomatic carriers and non-carriers frequently paralleled the differences between pre-symptomatic carriers and non-carriers, but in the pre-symptomatic group often fewer regions reached statistical significance or effect sizes were smaller.

The literature included in this review reported diffuse changes in white matter signal and global structural connectivity. These reflect the changes across regions and hemispheres that underpin emergent AD. There was significant overlap between the regions implicated by studies of APOE, autosomal-dominant AD genes and GWAS loci. This suggests

that although these genes are involved in different biological processes, these pathways may converge on a common final pathway resulting in a corresponding pattern of neurodegeneration. This is in keeping with the literature on AD pathology (Naj and Schellenberg, 2017). However, there was no evidence that microstructural changes were related to any individual microstructure component, as abnormalities were evident across white matter metrics.

4.2. Methodological considerations

The field has some key limitations (Jones and Cercignani, 2010; Jones, Knösche and Turner, 2013). Firstly, water diffusion is not a direct measure of neuroanatomy. Secondly, dMRI is an intrinsically noise-sensitive and low-resolution technique (Jones, Knösche and Turner, 2013). Several dMRI models assume fibre bundles to run parallel in a tract. However, fibres cross perpendicularly within voxels in many brain regions, which reduces the FA. The percentage of voxels containing crossing fibres is estimated to be ~ 90% (Jeurissen et al., 2013). It is also difficult to separate tracts that are closely aligned and then




Fig. 2. The change in the diffusion signal (isotropic to anisotropic diffusion) can result from multiple different pathologies. States that can produce the same signal change include axonal loss, demyelination, axonal growth or edema.

diverge (Tournier et al., 2011). DTI also demonstrates ‘degeneracy’: the same change in the diffusion tensor can be explained by multiple processes e.g., differently oriented fibre populations (‘crossing fibres’), or the ratio intra/extra-axonal space (see Fig. 2). Therefore dMRI is sensitive but lacks specificity (Jelescu et al., 2016a) and cannot provide an interpretable marker other than a vague concept of ‘tissue integrity’ (Wheeler-Kingshott and Cercignani, 2009).

4.3. Interpretation of dMRI signal change in AD

In addition to neurodegeneration, a number of different pathological processes can result in the same changes in diffusion signals. However, the presence of abnormal dMRI measures in AD correlates with other AD biomarkers, such as amyloid PET (Kantarci et al., 2014), CSF amyloid-beta and phosphorylated tau (Amlien et al., 2013; Gold et al., 2014; Li et al., 2015). Among those with AD, lower Mini-Mental State (MMSE) scores are associated with a greater effect size for FA in several brain areas, particularly the parietal region.

There is still much debate about the pathophysiology underpinning white matter changes in AD. For example, it is not clear whether white matter alterations are related to, or independent of, gray matter degeneration in AD. One hypothesis is that changes in white matter microstructure result from Wallerian degeneration (Coleman, 2005). According to this hypothesis, patterns of white matter alterations should correspond to grey matter pathology, occurring first in the hippocampal and entorhinal areas, before extending to wider temporal and parietal regions (Braak & Braak, 1997). Conversely, the theory of retrogenesis suggests that those tracts which are last to myelinate are the first to degenerate (Reisberg et al., 2002; Bartzokis, 2004). In this case, late-myelinating tracts would be affected first. It was striking that in the results of our systematic review there were no longitudinal dMRI studies comparing those at high and low genetic risk at different time points. Such debates cannot be resolved without serial imaging to assess dynamic changes in white matter signal.

Caution is required when interpreting diffusion metrics in AD. Some AD dMRI studies have concluded their findings showed disruption of myelin rather than axon damage based on the effect on LD relative to RD (Operto et al. 2018). Indeed, authors of ex-vivo studies in rats (Nevo

et al., 2001) and mice (Song et al., 2002) as well as a small study of cervical spondylosis patients (Ries et al., 2000) have suggested that a decrease in LD and increased in RD could potentially be used to differentiate demyelination from axonal injury. However, it may not be safe to generalize findings from controlled animal experiments and spinal cord studies to human brain, which has complex white matter architecture. Microstructural dMRI models (Assaf and Basser, 2005; Panagiotaki et al., 2012; Zhang et al., 2012), which aim to be more specific than dMRI by describing the signal as arising from a sum of tissue compartments, hold great promise, but the nonlinear fitting suffers from poor precision (Jelescu et al., 2016a). Furthermore, microstructural dMRI models do not account for water in myelin because it cannot be detected with common dMRI acquisitions. Measuring myelin content is relevant for monitoring pathologies where demyelination, dysmyelination and remyelination are implicated. Thus, despite dMRI signals being modulated by changes in myelin content through changes in intra/extra-axonal space (Jelescu et al., 2016b), it can only reveal ‘part of the picture’.

4.4. Strengths and limitations of this review

We followed PRISMA guidelines and used a comprehensive systematic search strategy to avoid missing relevant studies. We did not narrow our eligibility criteria to studies using particular research designs (e.g. case/control studies), samples (e.g. only clinical or healthy) or only young or older participants. We also included studies using any dMRI technique (e.g. TBSS, VBA or tractography-based ROI) or analysis (e.g. structural connectivity) to enhance our ability to evaluate how AD genetic risk is manifest in white matter. Unfortunately, any eligible studies in non-English language journals would have been overlooked. The methodology was heterogeneous. Even when the same techniques are applied there can be differences between scanners (Vollmar et al., 2010), and although some standardisation exists for DTI acquisition, other designs are largely ad hoc and can vary between centres. This meant that we were unable to perform a meta-analysis, could not establish the magnitude of effect sizes or assess for publication bias. The studies included in this review had a number of limitations. Some of the studies were probably underpowered. Authors often failed to describe sample ascertainment, making it more difficult to contextualise their results. The majority of studies included used either TBSS or VBA, which have a number of limitations, such as the requirement for spatial smoothing (Jones et al., 2005; Jones and Cercignani, 2010; Edden and Jones, 2011).

4.5. Potential clinical applications

As this review demonstrates, there is evidence that dMRI markers can detect changes in white matter microstructure in those with increased genetic risk of AD. The evidence suggests that some white matter tracts may be more sensitive than others, offering a possible marker of incipient disease. dMRI may also prove to be a useful tool for monitoring disease progression. However, dMRI presents a number of methodological challenges, and the biological changes that underpin alterations in dMRI signal are uncertain. However, with continuous improvements in imaging technology (McNab et al., 2013; Jones et al., 2018), and biophysical modeling (Novikov, Kiselev and Jespersen, 2018), we are likely to deepen our understanding of those biological underpinnings. Conventional T1- and T2- weighted images give established diagnostic markers and are widely used in clinical practice (Frisoni et al., 2010). The utility of dMRI as an adjunct to traditional structural assessment is as yet unproven. Beyond that, there are also practical challenges, such as the length of acquisition protocols, and a lack of standardisation of models, acquisition and analysis.

5. Conclusions

Despite some methodological limitations, the majority of the studies presented in this review demonstrate significant associations between AD genetic risk and diffusivity in white matter tracts. Specifically, lower FA and increased MD, RD and LD were found in a number of white matter tracts. This review emphasises the need for longitudinal studies of AD genetic risk to fully characterise white matter changes related to neurodegeneration across the lifespan. It is probable that very early pathology will be more amenable to therapeutic intervention. Therefore, early detection and pre-symptomatic treatment are vital. As acquisition and analysis techniques develop, dMRI is able to provide increasingly detailed information about the structure of white matter and brain connections and may develop useful biomarkers for AD pathology in future.

CRediT authorship contribution statement

Judith R. Harrison: Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing - review & editing. **Sanchita Bhatia:** Data curation, Investigation, Methodology, Project administration, Writing - review & editing. **Zhao Xuan Tan:** Investigation, Writing - review & editing. **Anastasia Mirza-Davies:** Investigation, Writing - review & editing. **Hannah Benkert:** Investigation, Writing - review & editing. **Chantal M.W. Tax:** Visualization, Methodology. **Derek K. Jones:** Supervision, Methodology.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

JH was supported by a Wellcome Trust GW4 Clinical Academic Fellowship. CT was Rubicon grant (680-50-1527) from the Netherlands Organisation for Scientific Research (NWO) and a Sir Henry Wellcome Fellowship (215944/Z/19/Z). DKJ and CT were both supported by a Wellcome Trust Investigator Award. DKJ by a Wellcome Trust Strategic Award (104943/Z/14/Z). We thank Dr Maxime Chamberland for his assistance with tract visualisation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nicl.2020.102359>.

References

Adluru, N., et al., 2014. White matter microstructure in late middle-age: effects of apolipoprotein E4 and parental family history of Alzheimer's disease. *Neuroimage Clin.* 4, 730–742. <https://doi.org/10.1016/j.nicl.2014.04.008>.

Alzheimer's association (2019) Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia Volume 15, Issue 3.

Amlien, I.K., et al., 2013. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. *Radiology* 266 (1), 295–303. <https://doi.org/10.1148/radiol.12120319>.

Assaf, Y., Basser, P.J., 2005. Composite hindered and restricted model of diffusion (CHARMED) MR imaging of the human brain. *Neuroimage* 27 (1), 48–58. <https://doi.org/10.1016/j.neuroimage.2005.03.042>.

Bagepally, B. et al. (2012) 'Altered white matter connectivity and atrophy at hippocampal subregions in Alzheimer's dementia and APOE-ε4 carriers', *Alzheimer's & Dementia*. Elsevier BV, 8(4), pp. P684–P685. doi: 10.1016/j.jalz.2012.05.1848.

Bagepally, B.S., et al., 2012b. Apolipoprotein E4 and brain white matter integrity in Alzheimer's disease: tract-based spatial statistics study under 3-tesla MRI. *Neurodegenerative Diseases* 10 (1–4), 145–148. <https://doi.org/10.1159/000334761>.

Bartzokis, G., 2004. Age-related myelin breakdown: a developmental model of cognitive

decline and Alzheimer's disease. *Neurobiol. Aging* 25 (1), 5–18 author reply 49–62.

Basser, P.J., Pierpaoli, C., 1996. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. *J. Magn. Resonance – Ser. B* 111 (3), 209–219. <https://doi.org/10.1006/jmrb.1996.0086>.

Bastin, M.E., et al., 2013. Quantitative tractography and tract shape modeling in amyotrophic lateral sclerosis. *J. Magn. Reson. Imaging* 38 (5), 1140–1145. <https://doi.org/10.1002/jmri.24073>.

Beaulieu, C. (2009) 'The Biological Basis of Diffusion Anisotropy', in *Diffusion MRI*. Elsevier, pp. 105–126. doi: 10.1016/B978-0-12-374709-9.00006-7.

Beaulieu, C., Allen, P.S., 1994. Water diffusion in the giant axon of the squid: implications for diffusion-weighted MRI of the nervous system. *Magn. Reson. Med.* 32 (5), 579–583. <https://doi.org/10.1002/mrm.1910320506>.

Bendlin, B. B. et al. (2012) 'CSF T-Tau/Aβ42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer's Disease', *PLoS ONE*. Edited by Y. He, 7(6), p. e37720. doi: 10.1371/journal.pone.0037720.

Benitez, A. et al. (2014) 'White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease', *NeuroImage: Clinical*. Elsevier, 4, pp. 64–71. doi: 10.1016/J.NICL.2013.11.001.

Bihan, D.L., 1995. Molecular diffusion, tissue microdynamics and microstructure. *NMR Biomed.* 8 (7), 375–386. <https://doi.org/10.1002/nbm.1940080711>.

Bis, J. C. et al. (2018) 'Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation', *Molecular Psychiatry*. Nature Publishing Group, pp. 1–17. doi: 10.1038/s41380-018-0112-7.

Boccaletti, S., et al., 2006. Complex networks: structure and dynamics. *Phys. Rep.* 175–308. <https://doi.org/10.1016/j.physrep.2005.10.009>.

Braak, H., Braak, E., 1995. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol. Aging*. Elsevier 16 (3), 271–278.

Braak, H., Braak, E., 1997. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. *Neurobiol. Aging* 18 (4 SUPPL.), S85–S88. [https://doi.org/10.1016/S0197-4580\(97\)00062-6](https://doi.org/10.1016/S0197-4580(97)00062-6).

Braskie, M.N., et al., 2011. Common Alzheimer's Disease Risk Variant Within the CLU Gene Affects white Matter Microstructure in young Adults. *J. Neurosci.* 31 (18), 6764–6770.

Brown, J.A., Terashima, K.H., Burggren, A.C., Ercoli, L.M., Miller, K.J., Small, G.W., Bookheimer, S.Y., 2011. Brain network local interconnectivity loss in aging APOE-4 allele carriers. *Proc. Natl. Acad. Sci.* 108 (51), 20760–20765. <https://doi.org/10.1073/pnas.1109038108>.

Büchel, C., et al., 2004. White matter asymmetry in the human brain: A diffusion tensor MRI study. *Cereb. Cortex* 14 (9), 945–951. <https://doi.org/10.1093/cercor/bbh055>.

Bullmore, E., Sporns, O., 2009. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat. Rev. Neurosci.* 10 (3), 186–198. <https://doi.org/10.1038/nrn2575>.

Caballero, M.A., et al., 2018. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. *Brain* 141 (10), 3065–3080.

Cai, S., et al., 2017. Modulation on brain gray matter activity and white matter integrity by APOE ε4 risk gene in cognitively intact elderly: a multimodal neuroimaging study. *Behav. Brain Res.* Elsevier B.V. 322, 100–109. <https://doi.org/10.1016/j.bbr.2017.01.027>.

Cavedo, E., et al., 2017. 'Disrupted white matter structural networks in healthy older adult APOE ε4 carriers – An international multicenter DTI study', *Neuroscience*. Pergamon 357, 119–133. <https://doi.org/10.1016/J.NEUROSCIENCE.2017.05.048>.

Chamberland, Maxime, et al., 2014. Real-time multi-peak tractography for instantaneous connectivity display. *Front. Neuroinform.* 8, 59. <https://doi.org/10.3389/fninf.2014.00059>.

Chen, Y., et al., 2015. Disrupted functional and structural networks in cognitively normal elderly subjects with the APOE epsilon 4 Allele. *Neuropsychopharmacology* 40 (5), 1181–1191. <https://doi.org/10.1038/npp.2014.302>.

Coleman, M., 2005. 'Axon degeneration mechanisms: commonality amid diversity'. *Nat. Rev. Neurosci.* 6 (11), 889–898. <https://doi.org/10.1038/nrn1788>.

Conturo, T.E., Lori, N.F., Cull, T.S., Akbudak, E., Snyder, A.Z., Shimony, J.S., McKinstry, R.C., Burton, H., Raichle, M.E., 1999. Tracking neuronal fiber pathways in the living human brain. *Proc. Natl. Acad. Sci. U.S.A.* 96 (18), 10422–10427. <https://doi.org/10.1073/pnas.96.18.10422>.

Corder, E.H., et al., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science (New York, N.Y.)* 261 (5123), 921–923.

Dell'Acqua, F., et al., 2015. Tract based spatial statistic reveals no differences in white matter microstructural organization between carriers and non-carriers of the APOE epsilon 4 and epsilon 2 alleles in young healthy adolescents. *J. Alzheimer's Dis. IOS Press* 47 (4), 977–984. <https://doi.org/10.3233/jad-140519>.

Dell'Acqua, F., Tournier, J., -Donal, 2019. Modelling white matter with spherical deconvolution: How and why? *NMR Biomed.* 32 (4), e3945. <https://doi.org/10.1002/nbm.3945>.

Dowell, N.G., et al., 2013. MRI of carriers of the apolipoprotein E ε4 allele-evidence for structural differences in normal-appearing brain tissue in ε4+ relative to ε4- young adults. *NMR Biomed.* 26 (6), 674–682. <https://doi.org/10.1002/nbm.2912>.

Edden, R.A., Jones, D.K., 2011. Spatial and orientational heterogeneity in the statistical sensitivity of skeleton-based analyses of diffusion tensor MR imaging data. *J. Neurosci. Methods* 201 (1), 213–219. <https://doi.org/10.1016/j.jneumeth.2011.07.025>.

Egli, S.C., et al., 2015. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample. *J. Alzheimer's Dis.* 44, 625–633. <https://doi.org/10.3233/JAD-141716>.

Elliott, L.T., et al., 2018. Genome-wide association studies of brain imaging phenotypes in

- UK Biobank. Nature 562 (7726), 210–216. <https://doi.org/10.1038/s41586-018-0571-7>.
- Englund, E., Brun, A., Alling, C., 1988. White matter changes in dementia of Alzheimer's type. *Brain* 111 (6), 1425–1439. <https://doi.org/10.1093/brain/111.6.1425>.
- Escott-Price, V., et al., 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain* 138 (12), 3673–3684. <https://doi.org/10.1093/brain/awv268>.
- Fletcher, E., et al., 2013. Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. *JAMA Neurol.* 70 (11), 1389. <https://doi.org/10.1001/jamaneurol.2013.3263>.
- Foley, S.F., et al., 2016. Multimodal brain imaging reveals structural differences in Alzheimer's disease polygenic risk carriers: a study in healthy young adults. *Biol. Psychiatry*. <https://doi.org/10.1016/j.biopsych.2016.02.033>.
- Frisoni, G.B., et al., 2010. The clinical use of structural MRI in Alzheimer disease. *Nat. Rev. Neurol.* 6 (2), 67–77. <https://doi.org/10.1038/nrneuro.2009.215>.
- Gatz, M., et al., 2006. Role of genes and environments for explaining Alzheimer disease. *Arch. General Psychiatry Am. Med. Assoc.* 63 (2), 168–174. <https://doi.org/10.1001/archpsyc.63.2.168>.
- Giulietti, G., et al., 2018. Whole brain white matter histogram analysis of diffusion tensor imaging data detects microstructural damage in mild cognitive impairment and alzheimer's disease patients. *J. Magn. Reson. Imaging*. <https://doi.org/10.1002/jmri.25947>.
- Gold, B. T. et al. (2014) 'White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults.', *Neurobiology of aging*. NIH Public Access, 35(10), pp. 2263–71. doi: 10.1016/j.neurobiolaging.2014.04.030.
- Guerreiro, R., et al., 2013. TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* 368 (2), 117–127. <https://doi.org/10.1056/NEJMoa1211851>.
- Van Hecke, W., et al., 2009. Comparing isotropic and anisotropic smoothing for voxel-based DTI analyses: a simulation study. *Hum. Brain Mapp.* <https://doi.org/10.1002/hbm.20848>.
- Heise, V., et al., 2011. The APOE ε4 allele modulates brain white matter integrity in healthy adults. *Mol. Psychiatry* 16 (9), 908–916. <https://doi.org/10.1038/mp.2010.90>.
- Honea, R. A. et al. (2009) 'Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study', *Journal of Alzheimer's disease*: JAD. NIH Public Access, 18(3), p. 553.
- Jelescu, I. O., Veraart, J., et al. (2016) 'Degeneracy in model parameter estimation for multi-compartmental diffusion in neuronal tissue', *NMR in Biomedicine*. John Wiley and Sons Ltd, 29(1), pp. 33–47. doi: 10.1002/nbm.3450.
- Jelescu, I.O., Zurek, M., et al., 2016b. In vivo quantification of demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy. *NeuroImage* 132, 104–114. <https://doi.org/10.1016/j.neuroimage.2016.02.004>.
- Jeurissen, B., et al., 2013. Investigating the prevalence of complex fiber configurations in white matter tissue with diffusion magnetic resonance imaging. *Hum. Brain Mapp.* 34 (11), 2747–2766. <https://doi.org/10.1002/hbm.22099>.
- Jeurissen, B., et al., 2019. Diffusion MRI fiber tractography of the brain. *NMR Biomed.* 32 (4), e3785. <https://doi.org/10.1002/nbm.3785>.
- Johansen-Berg, H. and Behrens, T. E. J. (2013) *Diffusion MRI: From Quantitative Measurement to In vivo Neuroanatomy: Second Edition, Diffusion MRI: From Quantitative Measurement to In vivo Neuroanatomy: Second Edition*. Elsevier Inc. doi: 10.1016/C2011-0-07047-3.
- Jones, D.K., et al., 2005. The effect of filter size on VBM analyses of DT-MRI data. *NeuroImage* 26 (2), 546–554. <https://doi.org/10.1016/j.neuroimage.2005.02.013>.
- Jones, D.K., 2011. *Diffusion MRI: Theory, Methods, and Applications*. Oxford University Press.
- Jones, D.K., Alexander, D.C., Bowtell, R., Cercignani, M., Dell'Acqua, F., McHugh, D.J., Miller, K.L., Palombo, M., Parker, G.J.M., Rudrapatna, U.S., Tax, C.M.W., 2018. Microstructural imaging of the human brain with a 'super-scanner': 10 key advantages of ultra-strong gradients for diffusion MRI. *NeuroImage* 182, 8–38. <https://doi.org/10.1016/j.neuroimage.2018.05.047>.
- Jones, D.K., Cercignani, M., 2010. Twenty-five pitfalls in the analysis of diffusion MRI data. *NMR Biomed.* 23 (7), 803–820. <https://doi.org/10.1002/nbm.1543>.
- Jones, D. K., Knösche, T. R. and Turner, R. (2013) 'White matter integrity, fiber count, and other fallacies: The do's and don'ts of diffusion MRI', *NeuroImage*. Academic Press, 73, pp. 239–254. doi: 10.1016/J.NEUROIMAGE.2012.06.081.
- Jones, D.K., Pierpaoli, C., 2005. Confidence mapping in diffusion tensor magnetic resonance imaging tractography using a bootstrap approach. *Magn. Reson. Med.* 53 (5), 1143–1149. <https://doi.org/10.1002/mrm.20466>.
- JW Gibbs (1898) 'Fourier's series', *nature.com*, 59(200).
- Kaden, E., Knösche, T.R., Anwander, A., 2007. Parametric spherical deconvolution: Inferring anatomical connectivity using diffusion MR imaging. *NeuroImage* 37 (2), 474–488. <https://doi.org/10.1016/J.NEUROIMAGE.2007.05.012>.
- Kantarci, K., et al., 2014. White matter integrity determined with diffusion tensor imaging in older adults without dementia. *JAMA Neurol.* 71 (12), 1547. <https://doi.org/10.1001/jamaneurol.2014.1482>.
- Kljajevic, V., et al., 2014. The ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. *Alzheimer's & Dementia* 10 (3), 401–404. <https://doi.org/10.1016/j.jalz.2013.02.008>.
- Koay, C.G., et al., 2006. A unifying theoretical and algorithmic framework for least squares methods of estimation in diffusion tensor imaging. *J Magn Reson* 182 (1), 115–125. <https://doi.org/10.1016/j.jmr.2006.06.020>.
- Kunkle, B.W., et al., 2019. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat. Genet.* 51 (3), 414–430. <https://doi.org/10.1038/s41588-019-0358-2>.
- Laukka, E.J., et al., 2015. Microstructural white matter properties mediate the association between APOE and perceptual speed in very old persons without dementia. *PLoS ONE* 10 (8), e0134766. <https://doi.org/10.1371/journal.pone.0134766>.
- Li, X., et al., 2015. White matter changes in familial Alzheimer's disease. *J. Intern. Med.* 278 (2), 211–218.
- Lyall, Donald M., Harris, Sarah E., Bastin, Mark E., Muñoz Maniega, Susana, Murray, Catherine, Lutz, Michael W., Saunders, Ann M., Roses, Allen D., Valdés Hernández, Maria del C., Royle, Natalie A., Starr, John M., Porteous, David. J., Wardlaw, Joanna M., Deary, Ian J., 2014. Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. *Neurobiol. Aging* 35 (6), 1513.e25–1513.e33. <https://doi.org/10.1016/j.neurobiolaging.2014.01.006>.
- Ma, Chao, Wang, Jun, Zhang, Junying, Chen, Kewei, Li, Xin, Shu, Ni, Chen, Yaojing, Liu, Zhen, Zhang, Zhanjun, 2017. Disrupted brain structural connectivity: pathological interactions between genetic APOE ε4 status and developed MCI condition. *Mol. Neurobiol.* 54 (9), 6999–7007. <https://doi.org/10.1007/s12035-016-0224-5>.
- Mayo, C.D., et al., 2017. Longitudinal changes in microstructural white matter metrics in Alzheimer's disease. *NeuroImage: Clinical*. <https://doi.org/10.1016/j.nicl.2016.12.012>.
- McNab, J.A., et al., 2013. The human connectome project and beyond: initial applications of 300mT/m gradients. *NeuroImage* 80, 234–245. <https://doi.org/10.1016/j.neuroimage.2013.05.074>.
- Mielke, M.M., et al., 2012. Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. *Alzheimer's & Dementia* 8 (2), 105–113. <https://doi.org/10.1016/J.JALZ.2011.05.2416>.
- Moher, D., et al., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann. Int. Med.* 151 (4), 264. <https://doi.org/10.7326/0003-4819-151-4-200908180-00135>.
- Naj, A.C., Schellenberg, G.D., 2017. Genomic variants, genes, and pathways of Alzheimer's disease: an overview. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 174 (1), 5–26. <https://doi.org/10.1002/ajmg.b.32499>.
- Nevo, U., et al., 2001. Diffusion anisotropy MRI for quantitative assessment of recovery in injured rat spinal cord. *Magn. Reson. Med.* 45 (1), 1–9.
- Newlander, S.M., et al., 2014. Methodological improvements in voxel-based analysis of diffusion tensor images: applications to study the impact of apolipoprotein e on white matter integrity. *J. Magn. Reson. Imaging* 39 (2), 387–397. <https://doi.org/10.1002/jmri.24157>.
- Nierenberg, J., et al., 2005. Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. *NeuroReport* 16 (12), 1369–1372. <https://doi.org/10.1097/01.wnr.0000174058.49521.16>.
- Novikov, D. S., Kiselev, V. G. and Jespersen, S. N. (2018) 'On modeling', *Magnetic Resonance in Medicine*. John Wiley and Sons Inc., pp. 3172–3193. doi: 10.1002/mrm.27101.
- Nyberg, L., Salami, A., 2014. The APOE ε4 allele in relation to brain white-matter microstructure in adulthood and aging. *Scand. J. Psychol.* 55 (3), 263–267. <https://doi.org/10.1111/sjop.12099>.
- O'Dwyer, L., et al., 2012. White matter differences between healthy young ApoE4 carriers and non-carriers identified with tractography and support vector machines. *PLoS ONE* 7 (4). <https://doi.org/10.1371/journal.pone.0036024>.
- Oishi, K., et al., 2012. The fornix sign: a potential sign for Alzheimer's disease based on diffusion tensor imaging. *J. Neuroimaging*. 22 (4), 365–374. <https://doi.org/10.1111/j.1552-6569.2011.00633.x>.
- Operto, G., et al., 2018. White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes. *Alzheimer's Res. Ther. BioMed Central* 10 (1), 48. <https://doi.org/10.1186/s13195-018-0375-x>.
- Panagiotaki, E., et al., 2012. Compartment models of the diffusion MR signal in brain white matter: a taxonomy and comparison. *NeuroImage* 59 (3), 2241–2254. <https://doi.org/10.1016/j.neuroimage.2011.09.081>.
- Parra, M.A., et al., 2015. Memory binding and white matter integrity in familial Alzheimer's disease. *Brain* 138 (Pt 5), 1355–1369.
- Perea, R.D., et al., 2018. Connectome-derived diffusion characteristics of the fornix in Alzheimer's disease. *NeuroImage Clin.* 19, 331–342. <https://doi.org/10.1016/J.NICL.2018.04.029>.
- Persson, J., et al., 2006. Altered brain white matter integrity in healthy carriers of the APOE ε4 allele: A risk for AD? *Neurology* 66 (7), 1029–1033.
- Petersen, R.C., Morris, J.C., 2005. Mild cognitive impairment as a clinical entity and treatment target. *Arch. Neurol.* 62 (7), 1160–1163.
- Pierpaoli, C., Basser, P.J., 1996. Toward a quantitative assessment of diffusion anisotropy. *Magn. Reson. Med.* 36 (6), 893–906. <https://doi.org/10.1002/mrm.1910360612>.
- Reisberg, B. et al. (2002) 'Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: management and treatment import.', *American journal of Alzheimer's disease and other dementias*, 17(4), pp. 202–12. doi: 10.1177/153331750201700411.
- Ries, M., et al., 2000. Diffusion tensor MRI of the spinal cord. *Magn. Reson. Med.* 44 (6), 884–892. [https://doi.org/10.1002/1522-2594\(200012\)44:6<884::AID-MRM9>3.0.CO;2-Q](https://doi.org/10.1002/1522-2594(200012)44:6<884::AID-MRM9>3.0.CO;2-Q).
- Ringman, J.M., et al., 2007. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. *Brain* 130 (7), 1767–1776. <https://doi.org/10.1093/brain/awm102>.
- Ryan, L., et al., 2011. Age-related differences in white matter integrity and cognitive function are related to APOE status. *NeuroImage* 54 (2), 1565–1577. <https://doi.org/10.1016/j.neuroimage.2010.08.052>.
- Ryan, N.S., et al., 2013. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. *Brain* 136 (5), 1399–1414. <https://doi.org/10.1093/brain/awt065>.
- Salminen, L.E., et al., 2013. Neuronal fiber bundle lengths in healthy adult carriers of the ApoE4 allele: a quantitative tractography DTI study. *Brain Imag. Behav.* 7 (3), 274–281. <https://doi.org/10.1007/s11682-013-9225-4>.
- Sanchez-Valle, R., et al., 2016. White matter abnormalities track disease progression in

- PSEN1 autosomal dominant Alzheimer's Disease. *J. Alzheimer's Dis.* JAD 51 (3), 827–835. <https://doi.org/10.3233/jad-150899>.
- Sexton, C.E., et al., 2011. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. *Neurobiol. Aging*. 32 (12), 2322.e5–2322.e18. <https://doi.org/10.1016/J.NEUROBIOLAGING.2010.05.019>.
- Slattery, C.F., et al., 2017. ApoE influences regional white-matter axonal density loss in Alzheimer's disease. *Neurobiol. Aging* 57, 8–17. <https://doi.org/10.1016/j.neurobiolaging.2017.04.021>.
- Smith, J.C., et al., 2016. Interactive effects of physical activity and APOE-ε4 on white matter tract diffusivity in healthy elders. *NeuroImage* 131, 102–112. <https://doi.org/10.1016/j.neuroimage.2015.08.007>.
- Smith, S.M., et al., 2006. Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. *NeuroImage* 31 (4), 1487–1505. <https://doi.org/10.1016/j.neuroimage.2006.02.024>.
- Smith, S.M., et al., 2007. Acquisition and voxelwise analysis of multi-subject diffusion data with tract-based spatial statistics. *Nat. Protoc.* 2 (3), 499–503. <https://doi.org/10.1038/nprot.2007.45>.
- Soares, J. M. et al. (2013) 'A hitchhiker's guide to diffusion tensor imaging', *Frontiers in Neuroscience*, (7 MAR). doi: 10.3389/fnins.2013.00031.
- Song, S.-K., et al., 2002. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. *NeuroImage* 17 (3), 1429–1436.
- Stang, A., 2010. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur. J. Epidemiol.* 25 (9), 603–605. <https://doi.org/10.1007/s10654-010-9491-z>.
- Stejskal, E. O. and Tanner, J. E. (1965) 'Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient', *J. Chem. Phys.* 42, p. 288. doi: 10.1063/1.1695690.
- Strijkers, G. J., Drost, M. R. and Nicolay, K. (2011) 'Diffusion MRI: Theory, methods, and applications'. Oxford University Press, pp. 672–689.
- Tang, S. X. et al. (2017) 'Diffusion characteristics of the fornix in patients with Alzheimer's disease', *Psychiatry Research: Neuroimaging*. Elsevier, 265, pp. 72–76. doi: 10.1016/J.PSYCHRESNS.2016.09.012.
- Tanzi, R. E. (2012) 'The genetics of Alzheimer disease', *Cold Spring Harbor perspectives in medicine*. Cold Spring Harbor Laboratory Press, 2(10), pp. 2157–1422.
- Thomason, M.E., Thompson, P.M., 2011. Diffusion imaging, white matter, and psychopathology. *Annu. Rev.* 7 (1), 63–85. <https://doi.org/10.1146/annurev-clinpsy-032210-104507>.
- Tournier, J.-D., Mori, S. and Leemans, A. (2011) 'Diffusion tensor imaging and beyond', *Magnetic resonance in medicine*. NIH Public Access, 65(6), pp. 1532–56. doi: 10.1002/mrm.22924.
- Vollmar, C., et al., 2010. Identical, but not the same: Intra-site and inter-site reproducibility of fractional anisotropy measures on two 3.0T scanners. *NeuroImage* 51 (4), 1384–1394. <https://doi.org/10.1016/j.neuroimage.2010.03.046>.
- Wai, Y.Y., et al., 2014. Tract-based spatial statistics: application to mild cognitive impairment. *Biomed Res. Int.* 2014. <https://doi.org/10.1155/2014/713079>.
- Wang, R., et al., 2015. Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline. *Neurology* 84 (11), 1128–1135. <https://doi.org/10.1212/WNL.0000000000001379>.
- Wasstheral, Jakob, et al., 2018. TractSeg - Fast and accurate white matter tract segmentation. *NeuroImage* 183, 239–253. <https://doi.org/10.1016/j.neuroimage.2018.07.070>.
- Wedeen, V.J., et al., 2005. Mapping complex tissue architecture with diffusion spectrum magnetic resonance imaging. *Magn. Reson. Med.* 54 (6), 1377–1386. <https://doi.org/10.1002/mrm.20642>.
- Westlye, L.T., et al., 2012. Effects of APOE on brain white matter microstructure in healthy adults. *Neurology* 79 (19), 1961–1969. <https://doi.org/10.1212/WNL.0b013e3182735c9c>.
- Wheeler-Kingshott, C.A.M., et al., 2012. A new approach to structural integrity assessment based on axial and radial diffusivities. *Funct. Neurol.* 27 (2), 85–90.
- Wheeler-Kingshott, C.A.M., Cercignani, M., 2009. About "axial" and "radial" diffusivities. *Magn. Reson. Med.* 61 (5), 1255–1260. <https://doi.org/10.1002/mrm.21965>.
- Winston, G. P. (2012) 'The physical and biological basis of quantitative parameters derived from diffusion MRI.', *Quantitative imaging in medicine and surgery*, 2(4), pp. 254–65. doi: 10.3978/j.issn.2223-4292.2012.12.05.
- Yeh, C. et al. (2020) 'Mapping Structural Connectivity Using Diffusion MRI: Challenges and Opportunities', *Journal of Magnetic Resonance Imaging*. John Wiley & Sons, Ltd, p. 88. doi: 10.1002/jmri.27188.
- Zhang, H., et al., 2012. NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage* 61 (4), 1000–1016. <https://doi.org/10.1016/j.neuroimage.2012.03.072>.
- Zhang, S. et al. (2015) 'Association of White Matter Integrity and Cognitive Functions in Chinese Non-Demented Elderly with the APOE ε 4 Allele', *Journal of Alzheimer's Disease*. IOS Press, 48(3), pp. 781–791. doi: 10.3233/JAD-150357.
- Zhuang, L., et al., 2012. Microstructural white matter changes in cognitively normal individuals at risk of amnesic MCI. *Neurology* 79 (8), 748–754. <https://doi.org/10.1212/WNL.0b013e3182661f4d>.